Colorectal Adenomatous Polyposis, Autosomal Recessive

"I think one of the things that we've really identified is that there are lots of players in telehealth and primary care, but we're the only ones really owning a complete genomic health experience," said Anne Wojcicki (center), CEO and co-founder of 23andMe, during CNBC's virtual Disruptor 50 summit last week. 23andMe launched 16 years ago offering at-home genetic testing kits for ancestry and for health. The company, which went public a year ago, has since amassed a huge database of genetic data based on its 13 million users. 23andMe has pivoted its strategy to leverage its trove of data for research and to make and sell its own therapies. The company also is expanding its core consumer genetic testing into a new business line called its genomic health service.  Last October, the company announced plans to buy Lemonaid Health, a virtual care and pharmacy provider, to integrate its personalized genetics service more deeply into primary care. The strategy is to use that acquisition as a foundation for 23andMe's genomic health service, where customers can access their genetic information for preventive and personalized care, executives said a year ago.  The key is to leverage Lemonaid Health's virtual care and online pharmacy capabilities to build out genetically driven telehealth and pharmacogenomic services. "You have no chance of really disrupting healthcare until you have scale. So, I think it's one thing, like even you look at the partnership between Amazon and JPMorgan, like all these things are really hard to significantly disrupt until you have scale," said Anne Wojcicki, CEO and co-founder of 23andMe, during CNBC's virtual Disruptor 50 summit last week. "The No. 1 priority for 23andMe was like, 'How am I going to get enough size and scale that people actually have to look at us as like a real force and a real player in healthcare?' Now, we have over 13 million people who all have their genetic information. I know, for instance, that these people are all taking their information to their clinicians. I now am forcing the conversation about how is genetics going to be used in a care setting," Wojcicki said. She continued, "So the next phase of the company is, 'How am I going to help millions and millions of people get access to their genetic information and now benefit from that?' And that was precisely why we bought the company Lemonaid. We now have a clinical team and a pharmacy team, and I'm going to pioneer really how we're going to be able to connect the 23andMe ecosystem with the traditional healthcare world." During the company's fiscal year 2023 first-quarter earnings call in August, 23andMe CFO Steve Schoch said developing the genomic health service remains a "high priority" for the company's consumer business. And the genomic health platform and the therapeutics business represent "key future growth opportunities." Back in May, the company began beta testing a genetic report consultation service with Lemonaid Health clinicians. This first phase of the integration focused on a subset of 23andMe’s genetic health risk reports related to hereditary breast and ovarian cancer syndrome caused by variants in the BRCA genes, MUTYH-associated polyposis (a hereditary colorectal cancer syndrome) and familial hypercholesterolemia, which can cause high cholesterol and early heart attacks. 23andMe+ members also have the opportunity to share information related to select pharmacogenetics reports.  It marked the first step in 23andMe’s plans to integrate genetics into primary care. The company plans to roll out the genomic health service more widely in 2023. Wojcicki told analysts on the call that the company should have more details on the genomic health service at the end of the year. "I think one of the things that we've really identified is that there are lots of players in telehealth and primary care, but we're the only ones really owning a complete genomic health experience. And, now, we're making sure that we get it right in terms of how we're going to price it and what it's going to look like, making sure that the healthcare providers we have are trained appropriately and putting together the protocols," Wojcicki told analysts during the first-quarter earnings call. "We're sort of in the thick of it in terms of what we're building and how we're going to roll it out." The company also recently made two key hires to strengthen its genomics leadership team. Noura Abul-Husn was named VP of genomic health. She previously was the founding chief of genomic medicine and clinical director of the Institute for Genomic Health at the Icahn School of Medicine at Mount Sinai. The company tapped Amy Sturm to serve as director of population health genomics. Sturm previously ran the MyCode genomic screening and counseling program at Geisinger Health System. "I think 23andMe has recognized over the last 16 years that people get their genetic information and then they take it to the medical world, and the medical world was not trained about how to use genetic information. Exactly what are the right protocols and what to do with it? Ultimately, we realized if we want to help our customers really benefit from the human genome, we need to have our own care team," Wojcicki said during the CNBC event. The company also is banking on the future of its therapeutics and research business.  In January, 23andMe announced it started clinical trials of its first drug developed entirely in-house, a cancer immunotherapy aimed at treating solid tumors. It's the second cancer drug the company has advanced into human trials, following an immuno-oncology therapy developed through a partnership with pharmaceutical giant GSK.  GSK also exercised its option to extend a partnership with 23andMe. The company will receive a one-time $50 million payment as part of that agreement.  23andMe now has a pipeline of more than 50 therapeutic programs, including two in phase 1 clinical trials, Wojcicki said during the first-quarter earnings call. Time will tell whetjer this pivot to drug development and genomic health services will supercharge the company's revenue growth. 23andMe still has massive losses, and investors have been disappointed with its weak revenue growth. 23andMe reported a $217 million net loss during its fiscal year 2022, which ended March 31, compared with $184 million during the prior year. The company brought in $272 million in revenue last year, up 11%. Schoch referred to 2022 as a "transitional year for 23andMe" during the company's full-year earnings call in May. In the most recent quarter, 23andMe's revenue grew 9% to $64 million. Consumer revenue was up 17% year over year due to the addition of telehealth revenue, the company reported.  Net loss during the quarter expanded to $90 million compared to a net loss of $42 million the same period a year ago, driven mainly by high operating expenses. The company is projecting full-year revenue for fiscal year 2023 to be between $260 million and $280 million, and the full-year GAAP net loss to be in the range of $350 million to $370 million.  23andMe's stock also has plunged 60% this year. During the most recent earnings call, analysts asked about 23andMe's path to profitability. Schoch noted that the company has $479 million in cash. "We also then reaffirmed our guidance on our adjusted EBITDA, which is our proxy for operating cash flow. And so when you look at those two figures, the range on adjusted EBITDA is $195 million to $215 million," he said. "If you kind of take the average of that and look at that cash balance, you can get a sense of what the runway is, and it's a reasonably good period of time; it will give us the ability to execute a lot of things that Anne [Wojcicki] has talked about on the consumer side and that Kenneth [Hillan, 23andMe’s head of therapeutics] is working on with our portfolio of therapeutics."

Achieved FY2022 financial guidanceFourth quarter and full year revenues of $101 million and $272 million representing 14% and 11% increases over prior year, respectivelyNew genomic health services expected in FY2023Webcast today, May 26, 2022, at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter (“Q4”) and full year of fiscal year 2022 (“FY2022”), which ended March 31, 2022. 23andMe is the only company with multiple FDA authorizations for over-the-counter genetic health risk reports, and in particular the only company that is FDA authorized to provide, without physician involvement, genetic cancer risk reports and medication insights on how individuals may process certain commonly prescribed medications based on their genetics. The company has also created the world’s largest crowdsourced platform for genetic research, which it is using to pursue drug discovery programs rooted in human genetics across a spectrum of disease areas. “We made incredible progress this last year with several major milestones, including our entry into the public markets, raising $560 million, and our acquisition of Lemonaid Health. In addition, we increased the number of health reports in our Personal Genome Service to over 60, grew our customer base to 12.8 million genotyped customers and expanded our therapeutics pipeline to more than 50 active programs with two now in Phase 1 clinical trials. All of these accomplishments further our mission to help people access, understand and benefit from the human genome,” said Anne Wojcicki, CEO and Co-Founder of 23andMe. “Genomic information is enabling us to revolutionize the diagnosis, prevention and treatment of human disease. The 23andMe Consumer business is focused on building a genomic health service that focuses on prevention and wellness. Our clinical efforts started with the acquisition and integration of Lemonaid Health’s telehealth and digital pharmacy services and will continue as we roll out a number of new services this fiscal year. Just this month we started beta testing a genetic report consultation service with clinicians who are trained in genetic health concepts. This service can help customers better understand the potential impact of their genetic risk profile and discuss the next steps. This is just the start of our efforts in this area, and I’m excited about the broader suite of services we plan to introduce later this year.” FY2022 Financial Results Summary Achieved financial guidance $272 million revenue [guidance: $268 to $278 million]$217 million net loss [guidance: $(205) to $(220) million]$151 million adjusted EBITDA loss [guidance: $(148) to $(163) million] Solid balance sheet with cash of $553 million at year end. Recent Highlights Began offering clinician-led genetic consultations to 23andMe customers focused on risk of breast cancer, colon cancer or early onset of heart disease based on the company’s BRCA1/BRCA2, MUTYH-associated polyposis and familial hypercholesterolemia reports.Enrolled patients in a Phase 1 study of the company’s first wholly owned immuno-oncology antibody, 23ME-00610 (23ME’610).Presented data at the American Association for Cancer Research (AACR) 2022 Annual Meeting related to the company’s wholly-owned 23ME’610 immuno-oncology program.Increased customer database to 12.8 million genotyped customers.Expanded 23andMe+ availability to customers in the UK and Canada. 23andMe+ is a membership service that offers insights and features to give members even more actionable information to live healthier lives.Launched four new reports for customers subscribed to 23andMe+ bringing total reports available to over 60. These new reports use machine learning to create a statistical model that estimates a person’s likelihood of developing a specific condition using thousands of genetic markers, along with a person’s ethnicity and birth sex. The new reports released in the fourth quarter were: Skin cancer reports (2)Diverticulitis reportIrritable bowel syndrome report Published three papers describing findings on how genetics influences depression and bipolar disorder Translational Psychiatry (2022) 12:121, educational attainment Nature Genetics (2022) 54, 437–449 and loss of smell and taste due to COVID-19 Nature Genetics (2022) 54, 121-124.Made Comparably’s 2022 list of Best Places to Work in the San Francisco Bay Area. “Our 2022 fiscal year was a pivotal year for 23andMe with our public listing in June 2021 followed by the strategically important acquisition of Lemonaid Health in November,” said Steve Schoch, Chief Financial Officer of 23andMe. “During that same time, our Personal Genome Service business increased by 1.5 million genotyped customers, or 13%, significantly extending our competitive data advantage. Our investments in our therapeutics portfolio have increased our pipeline to more than 50 active programs. Our Research Services business will be sustained by GSK’s election to remain our exclusive data partner for a fifth year for an opt-in cash payment of $50 million, double the average annual cash payment of the first four years. This extension is a clear sign of the value GSK sees in our data advantage.” “This coming fiscal year we plan to take a more cautious overall approach to our use of cash, giving priority to the roll out of our next-generation genomic health service, and to advancing our therapeutics efforts. We believe that appropriate investments in these areas will provide our best opportunities for future growth,” added Schoch. FY2022 Fourth Quarter and Full Year Financial Results Total revenue for the three and twelve months ended March 31, 2022, was $101 million and $272 million, respectively, representing increases of 14% and 11%, respectively, for the same periods in the prior year. Fourth quarter revenue growth was primarily due to the addition of three months of telehealth business revenue from our Lemonaid Health acquisition and higher Research Services revenue. These increases were partially offset by lower Personal Genome Service (“PGS”) revenue. Full year revenue growth was primarily driven by five months of telehealth business revenue and higher subscription revenue. Consumer services revenue represented approximately 83% and 82% of total revenue, respectively, for the three and twelve months ended March 31, 2022, and Research Services revenue, substantially all derived from the collaboration with GSK, accounted for approximately 17% and 18% of total revenue, respectively, for those same periods. Operating expenses for the three and twelve months ended March 31, 2022 were $117 million and $387 million, respectively, compared to $112 million and $302 million for the same periods in the prior year. The increase in fourth quarter operating expenses was primarily attributable to increased sales and marketing expenses associated with the addition of telehealth marketing activities. The increase in full year operating expenses was primarily due to increased sales and marketing spending around holiday and promotional periods, the addition of telehealth sales and marketing expenses and therapeutics-related research and development expenses as programs advance in development. Net loss for the three and twelve months ended March 31, 2022 was $70 million and $217 million, respectively, compared to net losses of $67 million and $184 million for the same periods in the prior year. The increase in net loss for the fourth quarter was primarily driven by higher operating expenses (as noted above). The increase in net loss in the full year was primarily driven by higher operating expenses (as noted above) offset by changes in fair value of warrant liabilities of $33 million and an income tax benefit of $3 million. In December 2021, the company redeemed all outstanding warrants. Total Adjusted EBITDA (as defined below) for the three and twelve months ended March 31, 2022 was $(30) million and $(151) million, respectively, compared to $(11) million and $(77) million for the same periods in the prior year. The decrease in total Adjusted EBITDA was driven primarily by the increase in operating expenses listed above. Adjusted EBITDA for the three and twelve months ended March 31, 2022 for the Consumer & Research Services segment was $3 million and $(30) million, respectively, compared to $18 million and $13 million for the same periods in the prior year. The decrease in this segment was driven primarily by the increase in operating expenses listed above, excluding therapeutics-related research and development expenses and one-time transaction costs. Balance Sheet 23andMe ended Q4 FY2022 with cash of $553 million, compared to $282 million as of March 31, 2021. The increase was primarily attributable to the $560 million in gross proceeds from the completion of the business combination with the Virgin Group Acquisition Corp during the first quarter of FY2022. FY2023 Financial Guidance The company’s full year fiscal 2023 guidance is based on a conservative approach, recognizing the current uncertainties in the general economy and in financial markets. Within the existing consumer businesses of PGS and telehealth, the company is prioritizing the minimization of cash burn over top-line growth. For those business segments expected to drive future growth, which include the company’s new genomic health services and Therapeutics, the company plans to focus on the most strategically and financially valuable options and invest appropriately. Because the new genomic health service is not anticipated to fully launch until later in the fiscal year, the company does not foresee meaningful revenue contribution from these new consumer products and services within FY2023. As a reminder, our guidance includes the full-year impact of the consolidation of Lemonaid Health’s business into the company’s overall consumer business as well as the current and anticipated effects of general inflation on certain of our costs. Revenue guidance for FY2023, which will end on March 31, 2023, is projected to be in the range of $260 to $280 million, with a net loss in the range of $350 to $370 million. Full year adjusted EBITDA loss is projected to be in the range of $195 to $215 million for fiscal year 2023. Conference Call Webcast Information 23andMe will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 26th, 2022 to discuss the financial results for the full year and Q4 FY2022 and report on business progress. The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations. A webcast replay will be available at the same address for a limited time within 24 hours after the event. About 23andMe 23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit investors.23andme.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding 23andMe’s strategy, financial position, funding for continued operations, cash reserves, projected costs, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject to other risks and uncertainties that are described in 23andMe’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on February 11, 2022 and in the reports subsequently filed by 23andMe with the SEC. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise. Use of Non-GAAP Financial Measure To supplement the 23andMe’s unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), this press release also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that 23andMe defines as net income before net interest expense (income), net other expense (income), changes in fair value of warrant liabilities, income tax (provision) benefit, depreciation and amortization of fixed assets, amortization of internal use software, amortization of acquired intangible assets, non-cash stock-based compensation expense, acquisition-related costs, litigation settlements not related to normal and continued business activities, and expenses related to restructuring and other charges, if applicable for the period. 23andMe has provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release. Adjusted EBITDA is a key measure used by 23andMe’s management and the board of directors to understand and evaluate operating performance and trends, to prepare and approve 23andMe’s annual budget and to develop short- and long-term operating plans. 23andMe provides Adjusted EBITDA because 23andMe believes it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry and it facilitates comparisons on a consistent basis across reporting periods. Further, 23andMe believes it is helpful in highlighting trends in its operating results because it excludes items that are not indicative of 23andMe’s core operating performance. In particular, 23andMe believes that the exclusion of the items eliminated in calculating Adjusted EBITDA provides useful measures for period-to-period comparisons of 23andMe’s business. Accordingly, 23andMe believes that Adjusted EBITDA provides useful information in understanding and evaluating operating results in the same manner as 23andMe’s management and board of directors. In evaluating Adjusted EBITDA, you should be aware that in the future 23andMe will incur expenses similar to the adjustments in this presentation. 23andMe’s presentation of Adjusted EBITDA should not be construed as an inference that future results will be unaffected by these expenses or any unusual or non-recurring items. Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the same industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA as a tool for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than net loss, which is the most directly comparable financial measure calculated in accordance with GAAP. Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. When evaluating 23andMe’s performance, you should consider Adjusted EBITDA alongside other financial performance measures, including net loss and other GAAP results. Investor Relations Contact: investors@23andme.com Media Contact: press@23andMe.com 23andMe Holding Co. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (Unaudited) Three Months Ended March 31, Year Ended March 31, 2022 2021 2022 2021 Revenue (related party amounts of $16,783 and $9,696 for the three months ended March 31, 2022 and 2021, respectively, and $46,064 and $39,917 for the years ended March 31, 2022 and 2021, respectively) $100,559 $88,582 $271,893 $243,920 Cost of revenue (related party amounts of $90 and $(808) for the three months ended March 31, 2022 and 2021, respectively, and $299 and $(1,400) for the years ended March 31, 2022 and 2021, respectively) 53,502 44,053 138,948 126,914 Gross profit 47,057 44,529 132,945 117,006 Operating expenses: Research and development (related party amounts of $5,769 and $7,997 for the three months ended March 31, 2022 and 2021, respectively, and $23,954 and $18,684 for the years ended March 31, 2022 and 2021, respectively) 50,324 45,596 189,377 159,856 Sales and marketing 29,351 11,955 100,338 43,197 General and administrative 36,836 54,055 97,383 99,149 Total operating expenses 116,511 111,606 387,098 302,202 Loss from operations (69,454) (67,077) (254,153) (185,196)Other (expense) income: Interest (expense) income, net 64 60 277 255 Change in fair value of warrant liabilities — — 32,989 — Other (expense) income, net (122) 4 (83) 1,322 Loss before income taxes (69,512) (67,013) (220,970) (183,619)Benefit from (provision for) income taxes (32) — 3,480 — Net loss $(69,544) $(67,013) $(217,490) $(183,619)Other comprehensive income 215 — 179 — Total comprehensive loss $(69,329) $(67,013) $(217,311) $(183,619)Net loss per share of Class A and Class B common stock attributable to common stockholders: Basic and diluted $(0.16) $(0.59) $(0.60) $(1.84)Weighted-average shares used to compute net loss per share: Basic and diluted 444,139,193 113,336,281 361,528,119 99,660,786 23andMe Holding Co. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) (Unaudited) March 31, 2022 2021 ASSETS Current assets: Cash $553,182 $282,489 Restricted cash 1,599 1,399 Accounts receivable, net 3,380 2,481 Inventories 10,789 6,239 Deferred cost of revenue 7,700 5,482 Prepaid expenses and other current assets 25,139 15,485 Total current assets 601,789 313,575 Property and equipment, net 49,851 60,884 Operating lease right-of-use assets 55,577 63,122 Restricted cash, noncurrent 6,974 6,974 Internal-use software, net 9,635 6,889 Intangible assets, net 73,905 — Goodwill 351,744 — Other assets 2,593 654 Total assets $1,152,068 $452,098 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable (related party amounts of $12,567 and $4,422 as of March 31, 2022 and 2021, respectively) $37,930 $12,271 Accrued expenses and other current liabilities (related party amounts of $5,772 and $7,065 as of March 31, 2022 and 2021, respectively) 44,588 31,953 Deferred revenue (related party amounts of $9,181 and $30,140 as of March 31, 2022 and 2021, respectively) 62,939 71,255 Operating lease liabilities 7,784 6,140 Total current liabilities 153,241 121,619 Operating lease liabilities, noncurrent 78,524 87,582 Other liabilities 4,647 1,165 Total liabilities $236,412 $210,366 Commitments and contingencies Redeemable convertible preferred stock Redeemable convertible preferred stock, $0.0001 par value per share, 10,000,000 shares authorized as of March 31, 2022, and $0.00001 par value per share, 209,512,070 shares authorized as of March 31, 2021; nil and 209,181,855 shares issued and outstanding as of March 31, 2022 and 2021, respectively; aggregate liquidation preference of nil and $874,107 as of March 31, 2022 and 2021, respectively — 837,351 Stockholders' equity (deficit) Common Stock - Class A shares, par value $0.0001, 1,140,000,000 and 390,921,975 shares authorized and 228,174,718 and 20,713,076 shares issued and outstanding as of March 31, 2022 and 2021, respectively; Class B shares, par value $0.0001, 350,000,000 and 380,944,977 shares authorized and 220,637,603 and 103,816,708 shares issued and outstanding as of March 31, 2022 and 2021, respectively; Class C shares, par value $0.0001, nil and 72,276,062 shares authorized and no shares issued and outstanding as of March 31, 2022 and 2021, respectively 45 12 Additional paid-in capital 2,110,160 381,607 Accumulated other comprehensive income 179 — Accumulated deficit (1,194,728) (977,238)Total stockholders’ equity (deficit) 915,656 (595,619)Total liabilities and stockholders’ equity (deficit) $1,152,068 $452,098 23andMe Holding Co. Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited) Year Ended March 31, 2022 2021 Cash flows from operating activities: Net loss $(217,490) $(183,619)Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 23,699 18,078 Amortization and impairment of internal-use software 2,449 2,168 Stock-based compensation expense 57,933 88,425 Changes in fair value of warrant liabilities (32,989) — Loss on disposal of property and equipment 100 57 Gain on lease termination (15) (876)Changes in operating assets and liabilities: Accounts receivable (899) 3,912 Inventories (4,262) 7,884 Deferred cost of revenue (2,219) 1,163 Prepaid expenses and other current assets (10,077) 2,126 Operating lease right-of-use assets 7,078 10,288 Other assets (1,820) 573 Accounts payable (related party amounts of $8,145 and $191 for the years ended March 31, 2022 and 2021, respectively) 22,856 137 Accrued expenses and other current liabilities (related party amounts of $ (1,293) and $3,517 for the years ended March 31, 2022 and 2021, respectively) 8,316 82 Deferred revenue (related party amounts of $(20,959) and $(14,917) for the years ended March 31, 2022 and 2021, respectively) (8,799) (16,210)Operating lease liabilities (7,054) (8,528)Other liabilities (3,635) 88 Net cash used in operating activities (166,828) (74,252)Cash flows from investing activities: Purchases of property and equipment (3,968) (4,054)Purchases of intangible assets (patents) (5,500) — Proceeds from sale of property and equipment 1 838 Capitalized internal-use software costs (4,505) (3,320)Cash paid for acquisitions, net of cash acquired (94,165) — Net cash used in investing activities (108,137) (6,536)Cash flows from financing activities: Proceeds from issuance of redeemable convertible preferred stock — 82,500 Payments for issuance costs of redeemable convertible preferred stock — (232)Proceeds from exercise of stock options (related party amounts of nil and $67,359 for the years ended March 31, 2022 and 2021, respectively) 16,998 76,151 Payments of deferred offering costs (30,642) (3,084)Proceeds from issuance of common stock upon Merger 309,720 — Proceeds from PIPE (related party amounts of $25,000 and nil for the years ended March 31, 2022 and 2021, respectively) 250,000 — Proceeds from exercise of merger warrants 44 — Payment for warrant redemptions (116) — Net cash provided by financing activities 546,004 155,335 Effect of exchange rates on cash (146) — Net increase in cash and restricted cash 270,893 74,547 Cash and restricted cash—beginning of period 290,862 216,315 Cash and restricted cash—end of period 561,755 290,862 Supplemental disclosures of non-cash investing and financing activities: Purchases of property and equipment during the period included in accounts payable and accrued expenses 722 535 Stock-based compensation capitalized for internal-use software costs 1,166 637 Reclassification of transaction costs 3,971 — Vesting of related party early exercised stock options — 91,046 Assumption of merger warrants liability 75,415 — Deferred offering costs during the period included in accounts payable and accrued expenses — 887 Conversion of redeemable convertible preferred stock to common stock 837,351 — Redemption/exercise of Class A common stock warrants 42,354 — Stock consideration in acquisition of businesses, including fair value of common stock issued and fair value of stock-based awards that were vested 322,842 — Reconciliation of cash and restricted cash within the consolidated balance sheets to the amounts shown in the consolidated statements of cash flows above: Cash 553,182 282,489 Restricted cash, current 1,599 1,399 Restricted cash, noncurrent 6,974 6,974 Total cash and restricted cash $561,755 $290,862 23andMe Holding Co. Total Company and Segment Information and Reconciliation of Non-GAAP Financial Measures (in thousands) (Unaudited) The company’s revenue and Adjusted EBITDA by segment and for the total company is as follows: Three Months Ended March 31, Year Ended March 31, 2022 2021 2022 2021 Segment Revenue Consumer & Research Services $100,559 $88,576 $271,893 $243,866 Therapeutics — 6 — 54 Total revenue $100,559 $88,582 $271,893 $243,920 Segment Adjusted EBITDA Consumer & Research Services Adjusted EBITDA $3,120 $17,721 $(30,112) $12,796 Therapeutics Adjusted EBITDA (19,898) (19,848) (76,944) (58,734)Unallocated Corporate (1) (12,992) (9,033) (43,684) (30,587)Total Adjusted EBITDA $(29,770) $(11,160) $(150,740) $(76,525) Reconciliation of net loss to Adjusted EBITDA Net loss $(69,544) $(67,013) $(217,490) $(183,619)Adjustments: Interest (income) expense, net (64) (60) (277) (255)Other (income) expense, net 122 (4) 83 (1,322)Change in fair value of warrant liabilities — — (32,989) — Income tax provision (benefit) 32 — (3,480) — Depreciation and amortization 4,711 4,714 18,899 20,246 Amortization of acquired intangible assets 4,371 — 7,269 — Stock-based compensation expense 20,460 51,203 57,933 88,425 Acquisition-related costs (2) 192 — 9,362 — Litigation settlement (3) 9,950 — 9,950 — Total Adjusted EBITDA $(29,770) $(11,160) $(150,740) $(76,525) Certain expenses such as Finance, Legal, Regulatory and Supplier Quality, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM. These amounts are included in Unallocated Corporate.For the fiscal years ended March 31, 2022, acquisition-related costs primarily consisted of advisory, legal and consulting fees related to the Lemonaid Acquisition.For the fiscal year ended March 31, 2022, litigation settlement is litigation cost net of insurance recoveries, which is not expected to occur on a recurring basis and not part of the company's normal and continued business activity.